Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 2 - Studien 11 bis 20 von insgesamt 59
- Rekrutierung läuftA phase 1 study evaluating the safety, tolerability and pharmacokinetics of AMG 757 in subjects with small cell lung cancerMolekulare Marker
- Rekrutierung läuftAnti-hormonelle Erhaltungstherapie mit oder ohne den CDK 4/6 Inhibitor Riboclib nach Erstlinien-Chemotherapy bei Patienten mit Hormon Rezeptor-positiven und HER2neu negativen Brustkrebs.Indikationen
- Rekrutierung läuftA single arm phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in combination with cetuximab in subjects with unresectable stage III or stage IV cutaneous squamous cell carcinoma (cSCC)IndikationenMolekulare Marker
- Rekrutierung läuftA Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T
cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and
Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in
Subjects with Relapsed and Lenalidomide-Refractory Multiple MyelomaMolekulare Marker - Rekrutierung läuft
EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA Mutation
Indikationen - Rekrutierung läuftA Phase 1/2, Multicenter, Open-Label Study to Assess Safety, Pharmacokinetics, and preliminary efficacy of CC-220, alone and in combination with an anti-CD20 Monoclonal Antibody (MAB) in subjects with relapsed or refractory LymphomasMolekulare Marker
- Rekrutierung läuftA phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patient with corticosteroid-refractory chronic graft vs. host disease after allogenic stem cell transplantation (REACH 3)Molekulare Marker
- Rekrutierung läuftAn open-Label, multi-Center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued Treatment with ceritinibMolekulare Marker
- Rekrutierung läuftA prospective, multicentre phase-II trial of Acalabrutinib in very old (≥ 80y) or frail patients with treatment-naïve or relapsed/refractory CLL
- Rekrutierung läuftA Prospective, Open-Label, Multicenter Phase-2-Trial to Evaluate the Efficacy and Safety of Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients with Relapsed/Refractory CLLMolekulare Marker